<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289467</url>
  </required_header>
  <id_info>
    <org_study_id>ZX008-IS</org_study_id>
    <nct_id>NCT04289467</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory Infantile Spasms With Fenfluramine</brief_title>
  <official_title>A Phase II Study of Fenfluramine for Treatment of Refractory Infantile Spasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II clinical trial in which children with refractory infantile spasms (also
      called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate
      efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to
      treatment with vigabatrin and ACTH we will be invited to participate. Study participants will
      undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo
      repeat video-EEG to determine effectiveness. Patients with favorable response will have the
      opportunity to continue treatment for up to 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electroclinical response (Efficacy)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with resolution of epileptic spasms and hypsarrhythmia (if present at baseline) after 21 days of treatment, as determined by overnight video-electroencephalography (EEG) evaluation and caregiver seizure diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Computational electroencephalography response (Efficacy)</measure>
    <time_frame>12 months</time_frame>
    <description>Median and range of response quantified using the probability-weighted response index (PWRI), a novel computational electroencephalography measure of hypsarrhythmia burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (Safety and tolerability)</measure>
    <time_frame>12 months</time_frame>
    <description>Detailed accounting of all treatment-emergent adverse events, including number of participants with clinically-significant valvulopathy and/or pulmonary hypertension, as determined by echocardiography.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Infantile Spasm</condition>
  <arm_group>
    <arm_group_label>Fenfluramine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenfluramine</intervention_name>
    <description>Open-label</description>
    <arm_group_label>Fenfluramine treatment</arm_group_label>
    <other_name>Fenfluramine Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children ages 3 to 36 months, inclusive

          -  Clinical diagnosis of infantile spasms

          -  Continued epileptic spasms despite adequate treatment with ACTH and vigabatrin.

        Exclusion Criteria:

          -  Significant preexisting cardiovascular disease

          -  Exposure to any cannabinoid product within 14 days of screening

          -  Initiation or dose-titration of any second-line treatment for infantile spasms in the
             14 days prior to screening.

          -  Implantation of a vagal nerve simulator within 14 days of screening

          -  Initiation and maintenance of the ketogenic diet within 3 months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaun Hussain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Martinez</last_name>
    <phone>310-206-4037</phone>
    <email>angelamartinez@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaun Hussain, MD</last_name>
    <phone>310-206-4037</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Shaun Hussain, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Spasms, Infantile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenfluramine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

